Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 24 Sep 2026 · Editorial standards

Iparomlimab and Tuvonralimab is named as a drug or biological intervention in 67 clinical trials in our China trial register, 35 of which are recruiting. Lead sponsors include Hebei Medical University Fourth Hospital (5), Fudan University (5) and Sun Yat-sen University (5). Registered phases: Phase 2, Phase 1/2, Not applicable, Phase 3, Phase 1, Phase 4 and Phase 2/3. Conditions studied include Colon Cancer; Immunotherapy; Hepatocellular Carcinoma.

Clinical trials of Iparomlimab and Tuvonralimab

67 trials

NCT ID	Study	Phase	Status	Lead sponsor	Register
NCT06686576	A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer (ClinicalTrials.gov ↗) Colon Cancer	Phase 3	Recruiting	Qilu Pharmaceutical Co., Ltd.	China
NCT06786026	QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC (ClinicalTrials.gov ↗) TNBC, Triple Negative Breast Cancer	Phase 2	Recruiting	Fudan University	China
NCT06787183	SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases (ClinicalTrials.gov ↗) Locally Advanced Rectal Cancer With Liver Metastases	Phase 2	Recruiting	Fujian Cancer Hospital	China
NCT06897046	Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC (ClinicalTrials.gov ↗) Non-small Cell Lung Cancer (NSCLC), II-IIIB	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
NCT06908382	Neoadjuvant QL1706 Therapy for ESCC (ClinicalTrials.gov ↗) Locally Advanced Resectable Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Shandong Provincial Hospital	China
NCT06917092	QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer (ClinicalTrials.gov ↗) Endometrial Adenocarcinoma, Endometrial Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
NCT06949111	Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color） Colon Cancer	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
NCT06951997	QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer (ClinicalTrials.gov ↗) Metastatic Pancreatic Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
NCT07014150	Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma (ClinicalTrials.gov ↗) Hepatocellular Carcinoma Resectable	Phase 2	Recruiting	Peking Union Medical College Hospital	China
NCT07082179	A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer (ClinicalTrials.gov ↗) NSCLC	Phase 2	Recruiting	Jiangsu Cancer Institute & Hospital	China
NCT07090317	Iparomlimab and Tuvonralimab in HNSCC (ClinicalTrials.gov ↗) Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	China
NCT07091305	A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy (ClinicalTrials.gov ↗) Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy, Induction Therapy	Phase 2	Recruiting	Shanghai Chest Hospital	China
NCT07101744	Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma (NPC), First-line Treatment Failure Nasopharyngeal Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
NCT07127822	Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer (ClinicalTrials.gov ↗) Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer	Phase 2	Recruiting	Peking University	China
NCT07150247	Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer (ClinicalTrials.gov ↗) BRAF V600 Colorectal Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
NCT07165847	Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05) (ClinicalTrials.gov ↗) Immunotherapy, Gastric Cancer (GC), Radiotherapy	Phase 2	Recruiting	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	China
NCT07179900	Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma (ClinicalTrials.gov ↗) Hepatocellular Carcinoma	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
NCT07180160	Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer (ClinicalTrials.gov ↗) Advanced Breast Cancer	Phase 2	Recruiting	Wenjin Yin	China
NCT07232654	Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC (ClinicalTrials.gov ↗) LOCALLY ADVANCED CERVICAL CANCERS	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
NCT07256236	SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer (ClinicalTrials.gov ↗) Cervical Cancer	Phase 2	Recruiting	Fujian Cancer Hospital	China
NCT07286240	QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer (ClinicalTrials.gov ↗) Treatment of Recurrent Ovarian Cancer	Phase 2	Recruiting	Affiliated Cancer Hospital & Institute of Guangzhou Medical University	China
NCT07289997	Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) (ClinicalTrials.gov ↗) AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4, AFPGC	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
NCT07290010	The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma (ClinicalTrials.gov ↗) Esophageal Squamous Cell Carcinoma (ESCC)	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
NCT07327788	QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT (ClinicalTrials.gov ↗) Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin, Bevacizumab	Phase 2	Recruiting	Nanfang Hospital, Southern Medical University	China
NCT07328009	A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma (ClinicalTrials.gov ↗) Hepato Cellular Carcinoma (HCC)	Phase 2	Recruiting	Fudan University	China
NCT07330596	QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC (ClinicalTrials.gov ↗) NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 2	Recruiting	Anhui Provincial Cancer Hospital	China
NCT07384416	QL1706 Plus Lenvatinib in Previously Treated Penile Cancer (ClinicalTrials.gov ↗) Penile Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
NCT07392346	Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer (ClinicalTrials.gov ↗) Gastric Cancer Adenocarcinoma Metastatic	Phase 2	Recruiting	Dai, Guanghai	China
NCT07396324	Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer (ClinicalTrials.gov ↗) HR-positive/HER2-negative Breast Cancer	Phase 2	Recruiting	RenJi Hospital	China
NCT07646301	Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer (ClinicalTrials.gov ↗) Uterine Cervical Neoplasms, Locally Advanced	Phase 2	Recruiting	Sun Yat-sen University	China
NCT07776080	Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus (ClinicalTrials.gov ↗) HCC - Hepatocellular Carcinoma	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
NCT07256782	A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumor	Phase 1/2	Recruiting	Qilu Pharmaceutical Co., Ltd.	China
NCT07291947	PULSAR Combined With Immunotherapy and Chemotherapy (ClinicalTrials.gov ↗) Cholangiocarcinoma	Phase 1/2	Recruiting	Wang Xin	China
NCT07178171	A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC (ClinicalTrials.gov ↗) TNBC, Triple Negative Breast Cancer	Phase 1	Recruiting	Xijing Hospital	China
NCT07546383	A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ClinicalTrials.gov ↗) Squamous Cell Carcinoma of Head and Neck	Not applicable	Recruiting	The Second Affiliated Hospital of Hainan Medical University	China
NCT07004335	Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study (ClinicalTrials.gov ↗) PD-(L)1, CTLA-4, Advanced Melanoma	Phase 4	Not yet open	Hebei Medical University Fourth Hospital	China
NCT07729605	FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC (ClinicalTrials.gov ↗) Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC)	Phase 3	Not yet open	Sun Yat-sen University	China
NCT05976568	A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ClinicalTrials.gov ↗) Hepatocellular Carcinoma	Phase 2/3	Not yet open	Qilu Pharmaceutical Co., Ltd.	China
NCT06446388	Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumor	Phase 2	Not yet open	Qilu Pharmaceutical Co., Ltd.	China
NCT06750861	QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC (ClinicalTrials.gov ↗) Pancreatic Adenocarcinoma	Phase 2	Not yet open	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
NCT06751277	QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer (ClinicalTrials.gov ↗) Recurrent or Metastatic Endometrial Cancer	Phase 2	Not yet open	xiang yang	China
NCT07007728	Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis (ClinicalTrials.gov ↗) Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver	Phase 2	Not yet open	Peking University Cancer Hospital & Institute	China
NCT07041788	Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC (ClinicalTrials.gov ↗) Cancer	Phase 2	Not yet open	Second Affiliated Hospital of Nanchang University	China
NCT07070713	Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC (ClinicalTrials.gov ↗) Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy	Phase 2	Not yet open	Fujian Cancer Hospital	China
NCT07131501	A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma (ClinicalTrials.gov ↗) Hepatocellular Carcinoma, Immunotherapy, Preoperative	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
NCT07156682	QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer (ClinicalTrials.gov ↗) Colon Cancer, MSS/pMMR, QL1706	Phase 2	Not yet open	Qilu Hospital of Shandong University	China
NCT07246317	Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
NCT07286942	Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial (ClinicalTrials.gov ↗) NSCLC, NSCLC (Non-small Cell Lung Cancer)	Phase 2	Not yet open	Jiangsu Cancer Institute & Hospital	China
NCT07315035	QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer (ClinicalTrials.gov ↗) Gastric Cancer Stage III	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
NCT07353268	Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy. (ClinicalTrials.gov ↗) Colorectal Cancer	Phase 2	Not yet open	Tao Zhang	China
NCT07372079	Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy (ClinicalTrials.gov ↗) Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
NCT07413601	Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC) (ClinicalTrials.gov ↗) Triple Negative Breast Cancer Metastatic	Phase 2	Not yet open	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
NCT07446387	A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer (ClinicalTrials.gov ↗) Metastatic Colorectal Cancer (CRC)	Phase 2	Not yet open	Jiangsu Cancer Institute & Hospital	China
NCT07649473	QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study (ClinicalTrials.gov ↗) Colon Cancer, Synchronous Liver Metastases	Phase 2	Not yet open	Fujian Medical University	China
NCT07663513	Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer (ClinicalTrials.gov ↗) Ovarian Cancers	Phase 2	Not yet open	Fudan University	China
NCT07741617	A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma (ClinicalTrials.gov ↗) Urologic Neoplasms	Phase 2	Not yet open	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
NCT07828873	A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma (ClinicalTrials.gov ↗) Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2	Not yet open	The First Affiliated Hospital of Zhengzhou University	China
NCT07829874	Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer. (ClinicalTrials.gov ↗) Biliary Tract Cancer (BTC)	Phase 2	Not yet open	Fudan University	China
NCT06602063	Surgery for Relapsed Ovarian Cancer in Precision (ClinicalTrials.gov ↗) Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma	Phase 1/2	Not yet open	Shanghai Gynecologic Oncology Group	China
NCT06822985	QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma (ClinicalTrials.gov ↗) HCC - Hepatocellular Carcinoma	Phase 1	Not yet open	Wan-Guang Zhang	China
NCT07139587	The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (ClinicalTrials.gov ↗) Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Not applicable	Not yet open	Qingxia Li	China
NCT07538193	Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer (ClinicalTrials.gov ↗) Carcinoma, Non-Small-Cell Lung (NSCLC), Neoplasm Staging, Lymphatic Metastasis	Not applicable	Not yet open	Tang-Du Hospital	China
NCT06313970	First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 2	Active, closed	Fudan University	China
NCT06892925	QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors Biliary Tract Tumors	Phase 2	Active, closed	Eastern Hepatobiliary Surgery Hospital	China
NCT07205497	QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer (ClinicalTrials.gov ↗) Neoadjuvant Immunotherapy, Locally Advanced Cervical Cancer	Phase 2	Active, closed	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
NCT07776639	Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction (ClinicalTrials.gov ↗) Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma	Phase 2	Active, closed	Yongxu Jia	China
NCT06809530	Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis (ClinicalTrials.gov ↗) Leptomeningeal Metastasis, Pemetrexed, PD-1 Inhibitor	Phase 1/2	Active, closed	Guangzhou Medical University	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied

94 conditions

Condition (as registered)	Trials
Colon Cancer	4
Immunotherapy	4
Hepatocellular Carcinoma	3
HCC - Hepatocellular Carcinoma	2
Gastroesophageal Junction Adenocarcinoma	2
NSCLC	2
Neoadjuvant Therapy	2
Advanced Solid Tumor	2
TNBC, Triple Negative Breast Cancer	2
QL1706	2
Breast Cancer	2
Gastric Cancer Adenocarcinoma Metastatic	1
Gastric / Gastroesophageal Junction Adenocarcinoma	1
MSI-H Cancer	1
HR-positive/HER2-negative Breast Cancer	1
AFP Gastric or Gastroesophageal Junction Adenocarcinoma	1
PD-1/CTLA-4	1
AFPGC	1
Carcinoma, Non-Small-Cell Lung (NSCLC)	1
Neoplasm Staging	1
Lymphatic Metastasis	1
Hepatocellular Carcinoma Resectable	1
Preoperative	1
PD-1	1
Metastatic Colorectal Cancer (CRC)	1
Esophageal Squamous Cell Carcinoma (ESCC)	1
Ovarian Cancers	1
Gastric Adenocarcinoma	1
PD-(L)1	1
CTLA-4	1
Advanced Melanoma	1
Iparomlimab	1
Cancer	1
Hepatecellular Carcinoma	1
RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin	1
Bevacizumab	1
Type VP3/4 Portal Vein Tumor Thrombosis	1
Uterine Cervical Neoplasms	1
Locally Advanced	1
Cholangiocarcinoma	1

+ 54 more conditions in the trial records above.

Trials by country register

Register	Iparomlimab and Tuvonralimab trials
Clinical trials in China	67

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Iparomlimab and Tuvonralimab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Iparomlimab and Tuvonralimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Iparomlimab and Tuvonralimab

Clinical trials of Iparomlimab and Tuvonralimab

Conditions studied

Sponsors

Trials by country register

How this page is built